Trevi Therapeutics Announces Proposed $150M Public Offering to Fund Pivotal Clinical Trials

summarizeSummary

Trevi Therapeutics is proposing a public offering of $150 million in common stock, plus an over-allotment option, to finance the clinical development of its lead drug candidate, Haduvio, and extend its cash runway through 2029.

check_boxKey Events

• Proposed Public Offering

  Trevi Therapeutics is offering $150,000,000 of common stock in a public offering, with underwriters having a 30-day option to purchase an additional $22,500,000 in shares.

• Strategic Use of Proceeds

  The net proceeds are intended to fund the clinical development of Haduvio for chronic cough in IPF, non-IPF ILD, and RCC, as well as for working capital and general corporate purposes.

• Extended Cash Runway

  The company estimates that the anticipated net proceeds, combined with existing cash, will be sufficient to fund operating expenses and capital expenditure requirements through 2029, potentially through FDA approval for IPF.

• Dilution for Shareholders

  The offering will result in immediate dilution for new investors and potential future dilution if outstanding options, warrants, or pre-funded warrants are exercised.

auto_awesomeAnalysis

Trevi Therapeutics has filed a preliminary prospectus supplement for a substantial public offering of common stock, aiming to raise $150 million, with an option for underwriters to purchase an additional $22.5 million. This capital raise is critical for the clinical-stage biopharmaceutical company, as it is intended to fund the pivotal Phase 3 trials for Haduvio in IPF-related chronic cough, as well as Phase 2b trials for non-IPF ILD and refractory chronic cough. The company anticipates these proceeds, combined with existing cash, will extend its operational runway through 2029, potentially covering the development of Haduvio through FDA approval for IPF. While the offering will result in dilution for existing shareholders, it significantly de-risks the company's ability to achieve key clinical milestones and secure its financial future for several years.